Aptevo Therapeutics (APVO) Retained Earnings (2015 - 2026)
Aptevo Therapeutics (APVO) posted Retained Earnings of -$281.9 million for Q1 2026, down 2.47% sequentially from -$275.1 million in Q4 2025, and down 10.99% YoY from -$316.7 million in Q1 2025.
Aptevo Therapeutics (APVO) Retained Earnings (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Retained Earnings for 12 years, with the latest figure at -$281.9 million in Q1 2026.
- Quarterly Retained Earnings fell 10.99% year-over-year to -$281.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$281.9 million (down 10.99% YoY) and the FY2025 annual result came in at -$275.1 million, down 11.12% from the prior year.
- Retained Earnings eased to -$281.9 million in Q1 2026 per APVO's latest filing, from -$275.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$193.8 million in Q2 2022 and troughed at -$281.9 million in Q1 2026.
- A 5-year average of -$233.8 million and a median of -$230.3 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings dropped 14.98% in 2022, then increased 8.34% in 2023.
- Over 5 years, Retained Earnings stood at -$206.0 million in 2022, then decreased by 8.45% to -$223.4 million in 2023, then declined by 10.8% to -$247.6 million in 2024, then fell by 11.12% to -$275.1 million in 2025, then slipped by 2.47% to -$281.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$281.9 million, -$275.1 million, and -$269.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Aptevo Therapeutics | 3.19 Mn | -6.60 Mn | - | -288.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -288.26 Mn |
| Mar 31, 2026 | -281.91 Mn |
| Dec 31, 2025 | -275.12 Mn |
| Sep 30, 2025 | -269.22 Mn |
| Jun 30, 2025 | -260.19 Mn |
| Mar 31, 2025 | -253.99 Mn |
| Dec 31, 2024 | -247.58 Mn |
| Sep 30, 2024 | -241.27 Mn |
| Jun 30, 2024 | -236.16 Mn |
| Mar 31, 2024 | -230.28 Mn |
| Dec 31, 2023 | -223.45 Mn |
| Sep 30, 2023 | -217.55 Mn |
| Jun 30, 2023 | -211.21 Mn |
| Mar 31, 2023 | -203.26 Mn |
| Dec 31, 2022 | -206.04 Mn |
| Sep 30, 2022 | -201.39 Mn |
| Jun 30, 2022 | -193.75 Mn |
| Mar 31, 2022 | -221.76 Mn |
| Dec 31, 2021 | -214.06 Mn |
| Sep 30, 2021 | -207.79 Mn |